Chemokines that attract both dendritic cells (DC) and lymphocyte effectors can aid in cancer immunotherapy by enlisting host immune cells to recognize tumors of low immunogenicity. CCL21 mediates the recruitment and co-localization of naive lymphocytes and antigen-stimulated DC into T-cell zones of secondary lymphoid organs, facilitating T-cell activation. In this chapter, we discuss CCL21 as a novel agent to boost immune responses against cancer. Based on the findings on CCL21, it is anticipated that rational combinations with other treatment. modalities will improve the therapeutic efficacy of this chemokine and antitumor benefit in a broad range of solid tumors.
CITATION STYLE
Sharma, S., Srivastava, M. K., White, M. H., Schaue, D., John, M. S., Zhang, G., … Dubinett, S. (2017). CCL21. In Cancer Therapeutic Targets (Vol. 1–2, pp. 111–116). Springer New York. https://doi.org/10.1007/978-1-4419-0717-2_33
Mendeley helps you to discover research relevant for your work.